TY - JOUR
T1 - The role of B cells in heart failure and implications for future immunomodulatory treatment strategies
AU - García-Rivas, Gerardo
AU - Castillo, Elena Cristina
AU - Gonzalez-Gil, Adrian M.
AU - Maravillas-Montero, José Luis
AU - Brunck, Marion
AU - Torres-Quintanilla, Alejandro
AU - Elizondo-Montemayor, Leticia
AU - Torre-Amione, Guillermo
N1 - Funding Information:
This work was partially supported by the GIEE Medicina Cardiovascular y Metabolomica (Tecnologico de Monterrey, 0020209M01) as well as the Consejo Nacional de Ciencia y Tecnología (CONACYT) grants 151136, 133591, and 269399, and Fronteras de la Ciencia grant (0682). A.M.G.‐G. and A.T.‐Q. were supported by the Graduate Student Fellowship of CONACYT.
Publisher Copyright:
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Despite numerous demonstrations that the immune system is activated in heart failure, negatively affecting patients' outcomes, no definitive treatment strategy exists directed to modulate the immune system. In this review, we present the evidence that B cells contribute to the development of hypertrophy, inflammation, and maladaptive tissue remodelling. B cells produce antibodies that interfere with cardiomyocyte function, which culminates as the result of recruitment and activation of a variety of innate and structural cell populations, including neutrophils, macrophages, fibroblasts, and T cells. As B cells appear as active players in heart failure, we propose here novel immunomodulatory therapeutic strategies that target B cells and their products.
AB - Despite numerous demonstrations that the immune system is activated in heart failure, negatively affecting patients' outcomes, no definitive treatment strategy exists directed to modulate the immune system. In this review, we present the evidence that B cells contribute to the development of hypertrophy, inflammation, and maladaptive tissue remodelling. B cells produce antibodies that interfere with cardiomyocyte function, which culminates as the result of recruitment and activation of a variety of innate and structural cell populations, including neutrophils, macrophages, fibroblasts, and T cells. As B cells appear as active players in heart failure, we propose here novel immunomodulatory therapeutic strategies that target B cells and their products.
KW - B cells
KW - Heart failure
KW - Inflammation
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85086340115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086340115&partnerID=8YFLogxK
U2 - 10.1002/ehf2.12744
DO - 10.1002/ehf2.12744
M3 - Review article
C2 - 32533765
AN - SCOPUS:85086340115
SN - 2055-5822
VL - 7
SP - 1387
EP - 1399
JO - ESC Heart Failure
JF - ESC Heart Failure
IS - 4
ER -